Latest News

(UroToday.com) As a part of the kindey cancer oral abstract session, Dr. Toni Choueiri presented preliminary results from a phase 2 study of belzutifan (MK-6482) in combination with United States Federal Drug Administration (FDA)-approved multiple TKI, cabozantinib.  As covered in other presentations throughout this year’s American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), […]

(UroToday.com) In this presentation, Dr. W. Kimryn Rathmell first discussed various genetic pathways that have been identified in renal cell carcinoma (RCC) and related these pathways to ongoing work trying to utilize imaging technologies and other noninvasive strategies for improved RCC classification and detection. 

(UroToday.com) Renal cell carcinoma (RCC) is a diverse group of diseases, as work from multiple recent studies at the genomic and transcriptomic level has highlighted. In this talk, Dr. Hakimi discussed what is known about the heterogeneity in pathways to RCC inception, focusing on clear cell RCC. 

(UroToday.com) In this presentation, Dr. Manley focused on three topics that play a role in the metastatic spread of kidney cancers: EMT transformation, molecular subtypes and how they determine response to therapy, and how host immune cell receptor diversity may impact disease biology and treatment response. 

BACKGROUND Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.

(UroToday.com) Up to 40% of patients with localized renal cell carcinoma (RCC) will develop metastatic disease and unfortunately, adjuvant therapy trials to date have failed to demonstrate an overall survival benefit. Transcriptomic profiling of the RCC tumor microenvironment has revealed gene signatures predictive of response to therapies in the metastatic setting, as high expression of angiogenesis genes […]

(UroToday.com) Management of patients with localized or locally advanced renal cell carcinoma (RCC) involves surgical resection. However, 20-40% of all localized kidney cancer patients experience a recurrence. Adjuvant treatment in high-risk kidney cancer has not proven to successfully improve overall survival and the only drug approved so far in this setting is vascular endothelial growth factor […]

(UroToday.com) Renal cell carcinoma (RCC) accounts for ~80%‒90% of all kidney cancers worldwide, with metastatic RCC (mRCC) portending a poor prognosis with a historical 5-year relative survival of 13%. The mRCC treatment landscape is rapidly changing with the approval of new therapies, which has recently been broadened by the FDA approvals of immunotherapy monotherapy in November […]

(UroToday.com) The NIVOREN GETUG AFU 26 study is a French multicenter prospective study to evaluate the safety and efficacy of nivolumab in a broad “real world setting” in metastatic renal cell carcinoma (mRCC) after failure of 1 or 2 tyrosine kinase inhibitors. Initial results for this trial were presented at the 2019 GU ASCO annual meeting. […]

(UroToday.com) Lenvatinib is a multi-targeted TKI that is approved in combination with everolimus to treat patients with advanced renal cell carcinoma (RCC), following one prior antiangiogenic therapy. While the combination therapy regimen resulted in improvements in progression-free survival, patients treated with the regimen experience adverse events that often lead to dose reductions and interruptions.1 Study 218 […]